We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Enhanced Tuberculosis Case Detection Among Substitution Treatment Patients (TBIDU)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01290081
Recruitment Status : Completed
First Posted : February 4, 2011
Last Update Posted : February 4, 2011
Sponsor:
Collaborators:
LLC Corrigo
Ida-Viru Central Hospital, Department of Tuberculosis
Information provided by:
National Institute for Health Development, Estonia

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
The purpose of this study was to determine the prevalence of latent tuberculosis infection among injecting drug users and to conduct randomized controlled trial to evaluate a case management intervention aimed at increasing TB screening and treatment entry among injecting drug users referred from a methadone drug treatment program in Estonia.

Condition or disease Intervention/treatment Phase
Tuberculosis Other: Case management approach in referral to health care services Not Applicable

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 112 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Health Services Research
Official Title: Prevalence of Latent Tuberculosis and Enhanced Tuberculosis Case Detection Among Injecting Drug Users Receiving Methadone Substitution Treatment
Study Start Date : October 2007
Actual Primary Completion Date : January 2008
Actual Study Completion Date : January 2008

Resource links provided by the National Library of Medicine


Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Active Comparator: Active referral
Case management intervention group - study personnel scheduled the TB doctor appointment for the participant, reminded to keep it, and transportation to the clinic was organized when needed.
 Other: Case management approach in referral to health care services
Case management intervention aimed at increasing TB screening and treatment entry among injecting drug users referred from a methadone drug treatment program
No Intervention: Passive referral
Participants were instructed to schedule an appointment with TB services themselves.
 Other: Case management approach in referral to health care services
Case management intervention aimed at increasing TB screening and treatment entry among injecting drug users referred from a methadone drug treatment program


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Criteria

Inclusion Criteria:

  • Participation in substitution treatment program,
  • Age 18 years or more,
  • Able to read and write in Estonian or Russian,
  • Able to provide informed consent
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01290081


Locations
Layout table for location information
Estonia
LLC Corrigo
Jõhvi, Ida-Virumaa, Estonia, 41532
Sponsors and Collaborators
National Institute for Health Development, Estonia
LLC Corrigo
Ida-Viru Central Hospital, Department of Tuberculosis
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Layout table for additonal information
Responsible Party: Kristi Rüütel, National Institute for Health Development
ClinicalTrials.gov Identifier: NCT01290081    
Other Study ID Numbers: TBIDU-1230
First Posted: February 4, 2011    Key Record Dates
Last Update Posted: February 4, 2011
Last Verified: January 2008
Keywords provided by National Institute for Health Development, Estonia:
Tuberculosis
Injecting drug users
Case management
Additional relevant MeSH terms:
Layout table for MeSH terms
Tuberculosis
Mycobacterium Infections
Actinomycetales Infections
Gram-Positive Bacterial Infections
 Bacterial Infections
Bacterial Infections and Mycoses
Infections